Alnylam Pharmaceuticals

5 active phase 3 trials and 8 active phase 2 trials led by this company, mostly in transthyretin amyloidosis (attr) with cardiomyopathy, obesity, type 2 diabetes mellitus (t2dm). The ones with the nearest registered primary completion date still ahead:

• Apr 2027A Study to Evaluate ALN-2232 in Participants With ObesityPhase 2RecruitingObesity
• May 2027A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes MellitusPhase 2RecruitingType 2 Diabetes Mellitus (T2DM)
• Jun 2027HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMBPhase 2RecruitingVon Willebrand Disease (VWD)
• Aug 2027A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid AngiopathyPhase 2Active, not recruitingCerebral Amyloid Angiopathy
• Aug 2027A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMPhase 2Active, not recruitingObese or Overweight Healthy Volunteers
• Dec 2027TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyPhase 3RecruitingHereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

1 trial has a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.

Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.